Fertility and reproductive health Improved metabolic health can increase fertility, particularly for individuals with insulin resistance or PCOS
A weight-loss plateau is a normal and expected part of the process, even with GLP-1 medications like semaglutide
Consequently, 11.4 pounds of abdominal fat remain
In demand Over the last few years, prescriptions for diabetes and weight-loss drugs have skyrocketed in the United States
He specializes in medically supervised Ozempic treatments in New Jersey & Philadelphia
Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine